Finance

Lists
LH:NYSE
Labcorp Holdings Inc
USD 332,66
-0,73%
(-2,45) 1D
USD 332,66
0,00% (0,00)
After hours
Closed: 31 Aug., 16:00:08 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LH...
Open
USD 332,70
High
USD 335,84
Low
USD 329,64
Mkt. cap
26,98 mjd
Avg. vol.
726,34 k
Volume
0,00
Dividend
0,87%
Quarterly dividend
USD 0,72
Ex-dividend date
29 Mei 2026
P/E ratio
27,51
52-wk high
USD 341,80
52-wk low
USD 244,52
EPS
USD 12,09
Beta
0,88
Shares outstanding
81,10 m
No. of employees
71 k
Open
USD 332,70
High
USD 335,84
Low
USD 329,64
Mkt. cap
26,98 mjd
Avg. vol.
726,34 k
Volume
0,00
Dividend
0,87%
Quarterly dividend
USD 0,72
Ex-dividend date
29 Mei 2026
P/E ratio
27,51
52-wk high
USD 341,80
52-wk low
USD 244,52
EPS
USD 12,09
Beta
0,88
Shares outstanding
81,10 m
No. of employees
71 k
News stories
From web sources and news partners
Profile
Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S. Its Diagnostics Laboratories segment operates 2,000 patient service centers with more than 6,000 in-office phlebotomists in the United States. In addition to healthcare testing such as oncology testing, human immunodeficiency virus genotyping and phenotyping, it provides testing for: employment, DNA testing to determine parentage and to determine immigration eligibility, environmental issues, wellness, toxicology, pain management, and medical drug monitoring. It also provides 50 tests that patients can complete at home. It processes over 160 million tests per year. Approximately 10% of this segment’s revenue are from the U.S. Medicare health insurance program. Wikipedia
About Labcorp Holdings Inc
CEOAdam H. Schechter
Employees71 k
Founded1978
HeadquartersBurlington, Noord-Carolina, Verenigde State van Amerika
SectorHealth care provider
Websitelabcorp.com
Analyst ratings
Based on 12 analysts giving stock ratings to LH in the past 3 months
Strong buy
Buy
9
Hold
3
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for LH in the last 3 months.
Highest
Current USD 332,66
USD 361,00 (+8,52%)
Average
USD 336,10 (+1,03%)
Lowest
USD 306,00 (-8,01%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lisa Gill
J.P. Morgan
Buy
Maintained
-
-
08/26/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
USD 355,00
+6,7%
08/10/2026
David Westenberg
Piper Sandler
Hold
Reiterated
USD 309,00
-7,1%
08/04/2026
Kevin Caliendo
UBS
Buy
Maintained
USD 361,00
+8,5%
07/31/2026
Pito Chickering
Deutsche Bank
Hold
Reiterated
USD 306,00
-8%
07/31/2026
Erin Wright
Morgan Stanley
Buy
Maintained
USD 338,00
+1,6%
07/31/2026
David S Macdonald
Truist Financial
Buy
Reiterated
USD 350,00
+5,2%
07/31/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
USD 352,00
+5,8%
07/31/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
USD 360,00
+8,2%
07/30/2026
Luke Sergott
Barclays
Hold
Maintained
USD 320,00
-3,8%
07/31/2026
Jared Haase
William Blair
Buy
Maintained
-
-
07/30/2026
David Toung
Argus Research
Buy
Maintained
USD 310,00
-6,8%
06/02/2026
Unknown Analyst
Mizuho Securities
Buy
Reiterated
USD 320,00
-3,8%
05/27/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
USD 300,00
-9,8%
05/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
04/30/2026
Last report
30 Jul. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 4,99 / USD 4,77
+4,65%beat
Revenue / Est. (USD)
3,73 mjd / 3,71 mjd
+0,47%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
3,56 mjd
3,52 mjd
3,54 mjd
3,73 mjd
Cost of goods sold
2,54 mjd
2,52 mjd
2,52 mjd
2,62 mjd
Cost of revenue
2,54 mjd
2,52 mjd
2,52 mjd
2,62 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
552,40 m
549,70 m
551,00 m
577,20 m
Operating expense
621,90 m
622,30 m
626,60 m
655,30 m
Total operating expenses
3,16 mjd
3,14 mjd
3,15 mjd
3,27 mjd
Operating income
403,20 m
370,90 m
387,20 m
456,70 m
Other non operating income
700,00 k
1,90 m
-600,00 k
-3,50 m
EBT including unusual items
337,00 m
190,60 m
319,70 m
386,40 m
EBT excluding unusual items
341,30 m
315,20 m
333,20 m
391,50 m
Income tax expense
75,50 m
25,70 m
41,70 m
87,30 m
Effective tax rate
22,40%
13,48%
13,04%
22,59%
Other operating expenses
-
-
-
-
Net income
261,10 m
164,70 m
277,80 m
298,70 m
Net profit margin
7,33%
4,68%
7,85%
8,01%
Earnings per share
4,18
4,07
4,25
4,99
Interest and investment income
3,50 m
3,50 m
12,20 m
5,60 m
Interest expense
-56,00 m
-55,00 m
-55,10 m
-61,10 m
Net interest expenses
-52,50 m
-51,50 m
-42,90 m
-55,50 m
Depreciation and amortization charges
-
-
-
-
EBITDA
574,20 m
549,40 m
560,50 m
635,70 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme